Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.57 |
| ▸ | HTT | P42858 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12642965 | 0.86 | CNR1 (0.56) | ALDH1A1SMN1; SMN2HTTLMNATDP1 | |
| SCHEMBL8685682 | 0.83 | SLC2A1 (0.52) | ALDH1A1SMN1; SMN2HTTLMNATDP1 | |
| SCHEMBL28956658 | 0.81 | HRH1 (0.42) | ALDH1A1SMN1; SMN2HTTLMNATDP1 | |
| SCHEMBL17371736 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HTTLMNATDP1 | |
| SCHEMBL17371735 | 0.80 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTLMNATDP1 | |
| SCHEMBL10871748 | 0.79 | SLC22A12 (0.50) | ALDH1A1SMN1; SMN2HTTKMT2AMAPT | |
| SCHEMBL10871752 | 0.79 | SLC22A12 (0.50) | ALDH1A1SMN1; SMN2HTTKMT2AMAPT | |
| SCHEMBL28155884 | 0.79 | SLC22A12 (0.60) | ALDH1A1SMN1; SMN2HTTKMT2AMAPT | |
| SCHEMBL31005244 | 0.77 | SNCA (0.57) | ALDH1A1LMNAKMT2AMAPTMEN1 | |
| SCHEMBL29377589 | 0.77 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2HTTLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ALDH1A1 800/4885SMN1; SMN2 2521/4885HTT 3883/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | ALDH1A1 700/4885SMN1; SMN2 2406/4885HTT 4127/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ALDH1A1 737/4885SMN1; SMN2 2331/4885HTT 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.